Hyperfine (HYPR) Cash & Equivalents Growth (1y) (2021 - 2026)
Hyperfine (HYPR) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | -26.57% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 42.78% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 0.94% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -11.19% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | -4.66% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | -44.03% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 19.49% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 72.43% |
| 10 | Hyperfine | 89.43 Mn | 44.66 Mn | 1.98 Mn | 70.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.96% |
| Mar 31, 2026 | 23.22% |
| Dec 31, 2025 | -6.80% |
| Sep 30, 2025 | -52.88% |
| Jun 30, 2025 | -52.76% |
| Mar 31, 2025 | -47.64% |
| Dec 31, 2024 | -49.93% |
| Sep 30, 2024 | -46.43% |
| Jun 30, 2024 | -42.72% |
| Mar 31, 2024 | -39.24% |
| Dec 31, 2023 | -36.00% |
| Sep 30, 2023 | -35.52% |
| Jun 30, 2023 | -35.25% |
| Mar 31, 2023 | -35.62% |
| Dec 31, 2022 | -37.68% |
| Sep 30, 2022 | 102.34% |
| Jun 30, 2022 | 87.49% |
| Mar 31, 2022 | 87.38% |
| Dec 31, 2021 | 200.75% |